Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma

Trial Profile

Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma

Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma; Eosinophilia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 Status changed from recruiting to completed, based on the results published in the American Journal of Respiratory and Critical Care Medicine.
    • 15 Sep 2017 Primary endpoint (Blood eosinophil absolute number) has been met, according to the results published in the American Journal of Respiratory and Critical Care Medicine.
    • 15 Sep 2017 Primary endpoint (Sputum eosinophil percentage) has been met, according to the results published in the American Journal of Respiratory and Critical Care Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top